After years of delay, Novartis’ intrathecal Zolgensma hit its phase 3 goal, improving motor function in SMA Type 2 (ages 2–18).

Novartis paid billions for AveXis—delays highlight the complexity of gene therapies.

Hopefully, this positive news drives more investment in the space #genetherapies